Regulatory health agencies have updated guidance frameworks to allow continuous biometric data in late-stage clinical trials. The decision enables drug developers to evaluate patient responses outside traditional clinical settings.
Data Standardization Challenges
Pharmaceutical research teams are now focusing on standardizing raw sensor outputs to meet stringent data integrity requirements. Early data suggests remote monitoring reduces trial dropout rates by 18%.